Sustained Tumor Regression With Zenocutuzumab, a Bispecific Antibody Targeting Human Epidermal Growth Factor Receptor 2/Human Epidermal Growth Factor Receptor 3 Signaling, in NRG1 Fusion–Positive, Estrogen Receptor–Positive Breast Cancer After Progression on a Cyclin-Dependent Kinase 4/6 Inhibitor

Journal article published in 2022 by Elisa Fontana , Gonzalo Torga , Raluca Fostea , Susan Cleator, Ernesto Wasserman, Anastasia Murat, Hendrik-Tobias Arkenau 

This paper is made freely available by the publisher.

Full text: Download

Preprint: archiving forbidden

Postprint: archiving restricted

Upload

Published version: archiving forbidden

Policy details

Data provided by